Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
This study has been completed.
Information provided by (Responsible Party):
Morie Gertz, Mayo Clinic
First received: March 15, 2012
Last updated: January 20, 2014
Last verified: January 2014
This study examines the value of stem cell transplantation in managing light chain amyloidisis.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Reporting of Amyloidosis Stem Cell Transplantation Outcomes|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Mayo Clinic:
Primary Outcome Measures:
- Survival [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
|Study Start Date:||June 2011|
|Study Completion Date:||June 2013|
|Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
- How does age at diagnosis affect prognosis in primary amyloidosis?
- How do lab values at diagnosis such as Creatinine, AST/ALT, total serum protein, serum gamma globulin/immunoglobulin levels affect prognosis in primary amyloidosis?
- How does degree of organ involvement/number of organs involved affect prognosis in primary amyloidosis?
- How does initial treatment affect prognosis in primary amyloidosis?
4. How do the specifics the stem cell transplant protocol affect prognosis in primary amyloidosis?
Contacts and Locations